Patents Assigned to Universite Paris-Saclay
-
Patent number: 11165220Abstract: A structure includes a semiconductor support, a semiconductor region overlying the semiconductor support, a silicon nitride layer surrounding and straining the semiconductor region, and a metal foot separating the silicon nitride layer from the semiconductor support. The semiconductor region includes germanium. The semiconductor region can be a resonator of a laser or a waveguide.Type: GrantFiled: October 19, 2017Date of Patent: November 2, 2021Assignees: STMicroelectronics (Crolles 2) SAS, Universite Paris-Saclay, Centre National de la Recherche ScientifiqueInventors: Anas Elbaz, Moustafa El Kurdi, Abdelhanin Aassime, Philippe Boucaud, Frederic Boeuf
-
Publication number: 20210301344Abstract: The present application describes and claims a novel method for identifying and stratifying the risk of developing a BK virus nephropathy (“Nx BK-v” below) in patients having undergone a kidney transplant. This method uses an index combining at least three bio-markers: i) the intensity of the anti-BK-v memory T lymphocyte response (memory T lymphocytes which are specific to v, hereinafter “LTm anti-BK-v”), ii) the number of occurrences of incompatibility in the HLA alleles of class I and class II between the donor and the recipient of the graft, taking into account iii) the viral charge of the BK-v virus in the whole blood of the patient. The present method allows a very precise evaluation of the risk of developing an Nx BK-v during the months following the test with the aim of optimising the immuno-suppressive treatment in order to better preserve the transplanted kidney.Type: ApplicationFiled: June 18, 2019Publication date: September 30, 2021Applicants: UNIVERSITE PARIS-SACLAY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE - HOPITAUX DE PARISInventors: Yassine TAOUFIK, Antoine DURRBACH, Manon DEKEYSER
-
Publication number: 20210230140Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.Type: ApplicationFiled: April 26, 2019Publication date: July 29, 2021Applicants: UNIVERSITE PARIS-SACLAY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT GUSTAVE-ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Mouad ALAMI, Olivier PROVOT, Abdallah HAMZE, Ilhem KHELIFI, Timothée NARET, Sébastien APCHER, Romain DARRIGRAND
-
Patent number: 11066649Abstract: The invention relates to a method for inducing human cholangiocyte differentiation of progenitor cells called hepatoblasts. More specifically, the invention relates to a method for differentiating hepatoblasts to cholangiocytes by culturing said hepatoblasts with a particular medium having interleukin-6 (IL-6) activity. The differentiation method can specifically induce cholangiocyte differentiation from hepatoblasts, and the human cholangiocytes differentiated according to the invention may be useful for drug discovery for treatment of cholangiopathies and bioengineered livers.Type: GrantFiled: March 19, 2015Date of Patent: July 20, 2021Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ PARIS-SACLAY, UNIVERSITE DE RENNESInventors: Anne Dubart Kupperschmitt, Anne Weber Benarous, Anne Corlu, Noushin Dianat
-
Patent number: 11034646Abstract: Disclosed is a new method for the synthesis of unsymmetrical tertiary amines using alcohol and an imine, and to new tertiary amines.Type: GrantFiled: September 28, 2018Date of Patent: June 15, 2021Assignees: UNIVERSITE PARIS-SACLAY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Christophe Bour, Marie Jenny Jacqueline Vayer, Vincent Gandon
-
Publication number: 20210175677Abstract: A method for generating ultrashort pulses includes directing a master beam having ultrashort pulses and at least one slave beam through an optical gate material. The intensity of the slave beam upstream of the optical gate material is lower than that of the master beam upstream of the optical gate material. The optical gate material and the pulses of the master beam are chosen to induce a Kerr effect when the master beam passes through the optical gate material, the Kerr effect producing a modulation of the phase of the slave beam in association with pulses of the master beam when the slave beam passes through the optical gate material. The modulation of the phase of the slave beam is transformed into a modulation of the amplitude thereof using a complementary optical device to generate a slave beam downstream of the optical gate material having ultrashort pulses.Type: ApplicationFiled: April 19, 2019Publication date: June 10, 2021Applicants: ECOLE POLYTECHNIQUE, INSTITUT D'OPTIQUE GRADUATE SCHOOL (IOGS), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS SACLAYInventors: Dimitrios PAPADOPOULOS, Xavier DELEN, Frederic DRUON
-
Publication number: 20210161887Abstract: The present invention relates to novel bis-hydrazone derivatives of formula (I): wherein Ar1 and Ar2 may be identical or different and are each independently selected from the group consisting of groups of formula (II) and (III): Y1 and Z1 are independently CH or NRc+, provided that al least one of Y1 and Z1 is NRc+ and at least one of Y1 and Z1 is CH, and Ra, Rb, Rc, X2? and L as defined in the claims, or a hydrate or a solvate thereof. Compositions and kits comprising same are also described. Said bis-hydrazone derivatives of formula (I), compositions and kits are useful as drugs, in particular for treating or preventing cancers associated with the Epstein-Barr Virus.Type: ApplicationFiled: April 3, 2019Publication date: June 3, 2021Applicants: Universite de Bretagne Occidentale, Centre Hospitalier Regional Universitaire de Brest, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Institut Curie, Université de Paris, Univ Paris XIII Paris-Nord Villetaneuse, Universite Paris-SaclayInventors: Marc Blondel, Alicia Quillevere, Cécile Voisset, Maria José Lista, Robin Fahraeus, Chrysoula Daskalogianni, Rodrigo Prado-Martins, Marie-Paule Teulade-Fichou, Anton Granzhan, Claire Beauvineau, Oksana Reznichenko
-
Publication number: 20210107984Abstract: The disclosure relates to an antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes, and also to the use of this antibody for the treatment of diseases associated with the suppressor activity of regulatory T lymphocytes, in particular the treatment of cancer.Type: ApplicationFiled: December 23, 2020Publication date: April 15, 2021Applicants: Universite de Lille, Centre National de la Recherche Scientifique, Institut Gustave Roussy, Cellvax, Universite Paris SaclayInventors: Nadira Delhem, Pierre Busson, Olivier Morales, Clement Barjon, Dhafer Mrizak, Claire Lhuillier, Rami Mustapha
-
Patent number: 10941448Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.Type: GrantFiled: January 11, 2019Date of Patent: March 9, 2021Assignees: The Universite Paris-Saclay, The Assistance Publique-Hopitaux de Paris (APHP), The Institut National de la Sante et de la Recherche Medicale (INSERM), PML Screening, LLCInventors: Eli Hatchwell, Peggy S. Eis, Edward B. Smith, III, Yassine Taoufik
-
Publication number: 20210041457Abstract: The invention relates to a non-invasive process for evaluating the quality of one or more dense connective tissue(s) in a patient, comprising the following steps: a) Analyzing the profile of the microrelief of a cutaneous replica of a portion of the skin of said patient by at least one of the following step: a1. visually assessing on picture(s) of said cutaneous replica the line shape and the anisotropy of the lines; and/or a2. Determining, on picture(s) of said cutaneous replica, the roughness index of the microrelief with an optical sensor, b) identifying cutaneous replica of “stage 1”, representative of healthy skins, and cutaneous replica of “stage 2” representative of altered skins, a cutaneous replica of stage 2 being indicative of low quality of the one or more dense connective tissue(s) in the patients body.Type: ApplicationFiled: September 24, 2018Publication date: February 11, 2021Applicants: ECOLE CENTRALE DE LYON, UNIVERSITE PARIS-SACLAY, UNIVERSITE DE PARIS, ASSISTANCE PUBLIQUE - HOPITAUX DE PARISInventors: Thierry HOC, Jean-Charles AUREGAN, Morad BENSIDHOUM, Catherine BOSSER, Hassan ZAHOUANI
-
Patent number: 10917047Abstract: The present invention relates to a radiofrequency oscillator comprising an optical resonator being a ring waveguide allowing the propagation of a first wave in a first direction and of a second wave in a second direction, the second direction being opposite to the first direction, and the resonator comprising an active optical medium generating a first optical line from the first wave and a second optical line from the second wave, the resonator being in contact with a part made of a material featuring a magneto-optic effect, an applier of external magnetic field of adjustable intensity on the resonator generating a frequency offset between the first wave and the second wave, and a processing circuit converting the beat between the two optical lines in a radiofrequency signal.Type: GrantFiled: October 2, 2018Date of Patent: February 9, 2021Assignees: THALES, UNIVERSITE PARIS-SACLAY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Sylvain Combrie, Alfredo De Rossi, Abdelmadjid Anane, Paolo Bortolotti
-
Publication number: 20210030703Abstract: In most cases, cancer chemotherapy and immunotherapy fail to yield durable responses, and complete and permanent regression of established tumors are rare. Here the inventors show that so-called caloric restriction mimetics (CRMs), which are natural or synthetic compounds that pharmacologically mimic the effects of fasting or caloric restriction, can be used to enhance the probability of cancer cure. The administration of several chemically distinct CRMs (such as hydroxycitrate, lipoic acid and the natural polyamine spermidine) led to the complete regression and the induction of protective anticancer immune responses in mouse models. This effect was achieved when CRMs were combined with chemotherapy and immunotherapy targeting the immune checkpoint molecules CTLA-4 and/or PD-1. Hence, caloric restriction and CRMs can be used to sensitize cancers to chemo-immunotherapy.Type: ApplicationFiled: March 11, 2019Publication date: February 4, 2021Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE PARIS, SORBONNE UNIVERSITÉ, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), UNIVERSITÉ PARIS-SACLAYInventors: Guido KROEMER, Sarah LEVESQUE, Jonathan POL
-
Patent number: 10899838Abstract: The invention relates to an antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes, and also to the use of this antibody for the treatment of diseases associated with the suppressor activity of regulatory T lymphocytes, in particular the treatment of cancer.Type: GrantFiled: June 5, 2015Date of Patent: January 26, 2021Assignees: Universite de Lille, Centre National de la Recherche Scientifique, Institut Gustave Roussy, Cellvax, Universite Paris-SaclayInventors: Nadira Delhem, Pierre Busson, Olivier Morales, Clement Barjon, Dhafer Mrizak, Claire Lhuillier, Rami Mustapha
-
Patent number: 10842870Abstract: The present invention relates to humanized anti-human GPVI antibodies and uses thereof.Type: GrantFiled: August 5, 2016Date of Patent: November 24, 2020Assignees: ACTICOR BIOTECH, UNIVERSITE DE PARIS, UNIVERSITÉ PARIS-XIII, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE PARIS-SACLAYInventors: Philippe Billiald, Martine Jandrot-Perrus
-
Patent number: 10793892Abstract: The present invention relates to a method for detecting the presence of expanded-spectrum ß-lactamase (ß-lactamase hydrolyzing expanded-spectrum cephalosporin)-producing bacteria in a sample, said method comprising the steps of: a) performing cell lysis on a test sample in order to obtain an enzymatic suspension; b) reacting a fraction of the enzymatic suspension obtained in step a) with a reagent kit, said reagent kit comprising —expanded-spectrum ß-lactamase substrate selected from the group consisting of cephalosporins, aztreonam, and cephamycins, —a pH color indicator which will change color when the pH of the reaction mixture is comprised between 6.4 and 8.4, wherein a color change after step b) indicates the presence of expanded-spectrum ß-lactamase-producing bacteria in the test sample. The invention also relates to a reagent kit, to a microtiter plate and to their uses in detecting the presence of expanded-spectrum ß-lactamase producers in a test sample.Type: GrantFiled: November 16, 2012Date of Patent: October 6, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITÉ PARIS-SACLAY, ASSISTANTE PUBLIQUE HOPITAUX DE PARIS (APHP)Inventors: Patrice Nordmann, Laurent Dortet, Laurent Poirel
-
Patent number: 10626186Abstract: The invention relates to isolated single-domain antibodies (sdAb) directed against von Willebrand Factor (VWF) D?D3 domain and chimeric polypeptides comprising thereof such as blood clotting factors and their uses in therapy such as in the prevention and treatment of hemostatic disorders. The invention also rotates to a method of extending or increasing half-life of a therapeutic polypeptide comprising a step of adding to the polypeptide sequence of said therapeutic polypeptide at least one sdAb directed against VWF D?D3 domain.Type: GrantFiled: January 25, 2017Date of Patent: April 21, 2020Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris-SaclayInventors: Petrus Lenting, Gabriel Ayme, Cecile Denis, Olivier Christophe